Navidea Biopharmaceuticals Inc. (NAVB) said Thursday that the U.S. Food and Drug Administration has granted the company's request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the pivotal Phase 3 trial. The meeting will take place on September 1, 2021 through conference call.

Create Account

Dark

chart

exchange

Check out our Dark Pool Levels

Navidea Biopharmaceuticals Inc. (NAVB) said Thursday that the U.S. Food and Drug Administration has granted the company's request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the pivotal Phase 3 trial. The meeting will take place on September 1, 2021 through conference call.

RTTNews | Jul 15, 2021 07:55AM EDT

07:54 Thursday, July 15, 2021 (RTTNews.com) - Navidea Biopharmaceuticals Inc. (NAVB) said Thursday that the U.S. Food and Drug Administration has granted the company's request for an End-of-Phase 2 Type B meeting to discuss its ongoing program in Rheumatoid Arthritis and advancement to the pivotal Phase 3 trial. The meeting will take place on September 1, 2021 through conference call.

The meeting with the FDA will be centered on discussion of the results from the Company's completed Phase 2b NAV3-31 study, as well as the design of the planned Phase 3 trial, Navidea said in a statement.

Previously, the FDA had reviewed the interim data and provided pertinent feedback on progressing the remaining patient data and encouraged an End-of-Phase 2 meeting when complete.

Read the original article on RTTNews ( https://www.rttnews.com/3209338/navidea-biopharma-fda-meeting-on-rheumatoid-arthritis-to-take-place-on-sept-1.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved